Home › All Companies › BBNX › Annual Report

Beta Bionics, Inc. (BBNX) — Annual Report

AI-Powered SEC Filing Analysis

← All BBNX filings
Latest Annual Report Filed: 2026-02-24

Key Insights

  • Beta Bionics is a medical device company developing an artificial pancreas system, a key focus area in the diabetes market. The company has made progress with regulatory approval and is preparing for a planned IPO in January 2025.
  • The company has experienced revenue growth from its durable medical equipment and pharmacy benefit plan channels, though it remains pre-revenue overall. Continued investments in R&D and manufacturing capabilities are expected to drive future growth.
  • Beta Bionics has a substantial net operating loss and R&D tax credit carryforward, which could provide future tax benefits as the company becomes profitable. However, the fair value of certain warrant liabilities and equity instruments introduce accounting complexity.
Sentiment: Positive Significance: 7/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-02-24. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Beta Bionics, Inc.

Current Report Quarterly Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.